psoriasis in a proportion of patients based on improvement of ppPGA. Unlike other conventional monotherapeutic topical treatments, HP/TAZ’s mechanism of action is uniquely formulated with a novel polymeric emulsion technology, allowing active ingredients to penetrate the thickened epidermal barrier of the hands and/or feet.2 Topical treatment compliance tends to be poor amongst psoriasis patients.5 However, HP/TAZ's optimal moisturizing capabilities and low irritative features have likely contributed to adequate patient adherence as evidenced by 62% of patients being moderately or very satisfied with treatment.
This study shows the positive response of treatment with HP/ TAZ even in a population of patients with failure to mid-to-high potency topical corticosteroids. This is likely due to the synergistic anti-inflammatory and antiproliferative mechanisms of HP and TAZ.2 Limitations to consider are the small sample size and lack of extensive follow-up time. Randomized, placebo-controlled studies with larger sample size and follow-up post-treatment to monitor for recalcitrant disease may be of beneficial use. The results of this study suggest that HP/TAZ lotion may be effective for adults with moderate-to-severe palmoplantar plaque-type psoriasis possibly through penetration of topically applied medications.
This study shows the positive response of treatment with HP/ TAZ even in a population of patients with failure to mid-to-high potency topical corticosteroids. This is likely due to the synergistic anti-inflammatory and antiproliferative mechanisms of HP and TAZ.2 Limitations to consider are the small sample size and lack of extensive follow-up time. Randomized, placebo-controlled studies with larger sample size and follow-up post-treatment to monitor for recalcitrant disease may be of beneficial use. The results of this study suggest that HP/TAZ lotion may be effective for adults with moderate-to-severe palmoplantar plaque-type psoriasis possibly through penetration of topically applied medications.
DISCLOSURES
Alice B. Gottlieb has received honoraria as an advisory board member and consultant for AnaptsysBio, Avotres Therapeutics, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb Co., Incyte, Janssen, Eli Lilly, Novartis, Pfizer, Sun Pharmaceutical Industries, Inc., UCB, Dermavant, Sanofi, and Xbiotech. A.B. Gottlieb has received research/educational grants from Boehringer Ingelheim, Janssen, Ortho Dermatologics, Novartis, UCB, Xbiotech, and Sun Pharma. All funds go to Mount Sinai Icahn School of Medicine. Jenna Yousif, Folawiyo Babalola, Caroline Campbell, Jessica Vargas, and Krystal Mitchell have no conflicts of interest to disclose.
REFERENCES
1. StatPearls. Palmoplantar Psoriasis. Available at: https://www.ncbi.nlm.nih. gov/books/NBK448142/. Accessed: March 28, 2022
2. Lebwohl MG, Tanghetti EA, Stein Gold L, et al. Fixed-combination halobetasol propionate and tazarotene in the treatment of psoriasis: Narrative review of mechanisms of action and therapeutic benefits. Dermatol Ther (Heidelb). 2021;11(4):1157-1174. doi:10.1007/s13555-021-00560-6.
3. Gottlieb A, Sullivan J, van Doorn M, et al. Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial. J Am Acad Dermatol. 2017;76(1):70-80. doi:10.1016/j. jaad.2016.07.058.
4. Kornmehl H, Callis Duffin K, et al. Examination of treatment satisfaction instruments in psoriasis: 2017 results from the psoriasis working group of the international dermatology outcome measures (IDEOM). Dermatology. 2021;237(2):151-157. doi: 10.1159/000501582. Epub 2020 Jan 28.
5. Feldman SR, Præstegaard M, Andreasen AH, et al. Validation of the selfreported psoriasis treatment convenience scale (PTCS). Dermatol Ther (Heidelb). 2021;11(6):2077-2088. doi:10.1007/s13555-021-00626-5.
2. Lebwohl MG, Tanghetti EA, Stein Gold L, et al. Fixed-combination halobetasol propionate and tazarotene in the treatment of psoriasis: Narrative review of mechanisms of action and therapeutic benefits. Dermatol Ther (Heidelb). 2021;11(4):1157-1174. doi:10.1007/s13555-021-00560-6.
3. Gottlieb A, Sullivan J, van Doorn M, et al. Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial. J Am Acad Dermatol. 2017;76(1):70-80. doi:10.1016/j. jaad.2016.07.058.
4. Kornmehl H, Callis Duffin K, et al. Examination of treatment satisfaction instruments in psoriasis: 2017 results from the psoriasis working group of the international dermatology outcome measures (IDEOM). Dermatology. 2021;237(2):151-157. doi: 10.1159/000501582. Epub 2020 Jan 28.
5. Feldman SR, Præstegaard M, Andreasen AH, et al. Validation of the selfreported psoriasis treatment convenience scale (PTCS). Dermatol Ther (Heidelb). 2021;11(6):2077-2088. doi:10.1007/s13555-021-00626-5.
AUTHOR CORRESPONDENCE
Jenna Yousif BS jenna.yousif@med.wayne.edu
